BOSTON, May 23, 2005 – Zelos Therapeutics Inc., an early-stage therapeutics product development company, recently completed its $42.5 million Series B Preferred Stock financing.
The partner from Goodwin Procter who represented Zelos Therapeutics Inc. in this matter is Mitchell Bloom.
Related Content
- Big Molecule WatchApril 18, 2024
Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigation
- Big Molecule WatchApril 17, 2024
MDL Panel Grants Transfer of Aflibercept BPCIA Case
- Big Molecule WatchApril 11, 2024
FDA Approves BMS and J&J CAR-T Cell Therapies for the Earlier Treatment of Multiple Myeloma
- Life Sciences PerspectivesApril 10, 2024
Janssen v. Teva: Not an April Fool’s Day Joke for Life Sciences Companies
- Big Molecule WatchApril 9, 2024
FDA Approves New Indication for AstraZeneca and Daiichi Sankyo’s Cancer Drug ENHERTU
- Life Sciences PerspectivesApril 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond
- InsightApril 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond
- Big Molecule WatchMarch 29, 2024
REGENXBIO and Sarepta Agree to Stay Litigation Pending Outcome of Sarepta’s IPR Petition
- Awards and RankingsApril 18, 2024
Goodwin is Number One in the Q1 2024 League Table Rankings
- Press ReleaseApril 18, 2024
Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval
- Press ReleaseApril 17, 2024
Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma
- Press ReleaseApril 16, 2024
Goodwin Represents the Underwriters in PACS Group $450 Million IPO
- Press ReleaseApril 15, 2024
Goodwin Advises Exclusive Placement Agent in Acrivon Therapeutics’ $130 Million Private Placement
- Press ReleaseApril 10, 2024
Alpine Immune Sciences To Be Acquired by Vertex Pharmaceuticals For $4.9 Billion
- In the PressApril 9, 2024
Goodwin Picks Up Tech Team, Eyeing AI-Fueled Rebound (Bloomberg Law)
- In the PressApril 9, 2024
Deal Watch: M&A (Law.com)